Hepion Pharmaceuticals Stock Price, News & Analysis

Hepion Pharmaceuticals, Inc. (HEPA) is a clinical stage biopharmaceutical company that has undergone a significant strategic transition. According to company disclosures, Hepion had been developing a treatment for non-alcoholic steatohepatitis ("NASH"), hepatocellular carcinoma ("HCC"), and other chronic liver diseases, and is now repositioning itself as a developer and distributor of diagnostic tests for several conditions. The company is headquartered in New Jersey and its common stock trades under the symbol HEPA.

Hepion states that it is developing and commercializing diagnostic tests for celiac disease, respiratory multiplex testing (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC). Company news reports describe these as precision diagnostics intended to address areas of significant unmet clinical need, including underdiagnosed conditions such as celiac disease and H. pylori, as well as high-risk populations for liver cancer. Hepion indicates that some of these tests have CE marks and are eligible to be sold in Europe.

Historically, Hepion focused on drug development for chronic liver diseases. Its primary asset, rencofilstat, is described as a potent inhibitor of cyclophilins, which are involved in many disease processes. Company communications state that rencofilstat has been shown to reduce liver fibrosis and HCC tumor burden in experimental disease models. The therapeutic approach targeted fibrosis and inflammation and was intended to address complex pathologies related to the progression of liver disease, including NASH and viral hepatitis. Hepion reported that the U.S. Food and Drug Administration granted Fast Track designation for rencofilstat for the treatment of NASH and Orphan Drug designation for the treatment of HCC.

In its public updates, Hepion explains that it initiated a strategic restructuring plan to preserve capital by reducing operating costs and began exploring a range of strategic and financing alternatives. The company announced that it was winding down its ASCEND-NASH clinical trial, a Phase 2b, randomized, multi-center, double-blinded study designed to evaluate the safety and efficacy of rencofilstat in NASH. Hepion later reported that wind-down activities for this trial had been completed and that the trial had been closed.

Company news releases further note that Hepion has taken steps to monetize rencofilstat-related assets. Hepion disclosed that it entered into a patent and associated assets acquisition agreement to sell all patent assets, knowhow, clinical trial data and drug product relating to rencofilstat for a nominal amount in addition to a contingent value right to Hepion’s stockholders. The company has stated that, to the extent that cash is available, it is continuing efforts to provide any value derived from rencofilstat to its shareholders.

As part of its transition toward diagnostics, Hepion reports that it entered into a license agreement with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC. Company announcements describe that the celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe. Hepion characterizes this licensing opportunity as a way to access diagnostic tests that address a combined addressable market spanning multiple disease areas.

Hepion has also described its corporate and capital markets developments. The company announced a reverse stock split of its common stock, implemented with the stated intention of increasing the bid price to enable the company to regain compliance with Nasdaq’s minimum bid price requirement. Later, Hepion reported that it received a delisting notification from Nasdaq, indicating that the Nasdaq Hearings Panel had determined to delist the company’s shares due to failure to meet continued listing standards, including the minimum bid price requirement and concerns that Hepion was viewed as a public shell. Hepion stated that trading in its common stock on Nasdaq would be suspended and that it expected its common stock to be quoted on the OTC Markets Group under the symbol HEPA.

In a subsequent announcement, Hepion reported that it successfully completed the process of transitioning to the OTCQB Venture Market, with its common stock beginning to trade on the OTCQB under the symbol HEPA. This reflects a change in the company’s trading venue from Nasdaq to the OTCQB Venture Market while maintaining the same ticker symbol.

Hepion’s disclosures also reference a previously proposed merger with Pharma Two B Ltd., a late-clinical stage company developing a product candidate for Parkinson’s disease. The companies announced the filing and later the effectiveness of a registration statement related to the proposed merger, and Hepion communicated that its board had approved the transaction and scheduled a special meeting of stockholders to vote on it. A later company announcement reported that Hepion and Pharma Two B entered into a termination agreement that ended the merger agreement, and Hepion cancelled the related special meeting and withdrew the associated proposals.

In addition to its strategic and capital markets actions, Hepion has reported changes in leadership. Company news and SEC filings state that certain executives have resigned or been replaced, and that a new interim Chief Executive Officer has been appointed. Hepion characterizes this leadership change as part of a new chapter focused on strategic renewal, value creation, and diagnostic innovation, with an emphasis on repositioning the company in precision diagnostics and prioritizing near-term revenue generation and long-term innovation.

Overall, Hepion Pharmaceuticals presents itself as a biopharmaceutical company that has shifted from developing drug therapies for chronic liver diseases centered on rencofilstat to focusing on the development and commercialization of diagnostic tests for celiac disease, respiratory multiplex infections, H. pylori and HCC. Its public communications highlight this transition, its efforts to manage capital and strategic alternatives, and its change in listing status from Nasdaq to the OTCQB Venture Market.